SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...
Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback